Fibromyalgia · Evidence Update

A phenotype-driven guide to fibromyalgia treatment. This includes low-dose naltrexone and sublingual cyclobenzaprine, exercise, neuromodulation, the gut–brain axis, and personalized care.

Evidence summary based on: Bazzichi, L., Di Carlo, M., Salaffi, F., et al. (2026). Therapeutic advances in fibromyalgia: one year in review 2026. Clinical and Experimental Rheumatology, 44(6), 1069–1081. 

Key takeaways at a glance

• No breakthrough drug emerged in 2025; progress came from new formulations, drug repositioning, and mechanism-based thinking.
• SNRIs (duloxetine, milnacipran) and gabapentinoids (pregabalin) remain the pharmacological backbone, helping roughly 30–50% of patients.
• Sublingual cyclobenzaprine (TNX-102 SL) is the most notable new formulation, targeting sleep and pain.
• Structured, supervised, and digitally supported exercise is the strongest non-drug intervention.
• The central theme: treat fibromyalgia by patient phenotype, not with a one-size-fits-all protocol.

Why fibromyalgia treatment is being rethought

Fibromyalgia (FM) is a chronic nociplastic pain syndrome, a disorder of how the nervous system processes pain rather than a disease of damaged joints or inflamed tissue. It is defined by widespread musculoskeletal pain, persistent fatigue, non-restorative sleep, and cognitive difficulty often described as "fibro fog." It frequently overlaps with mood disorders, irritable bowel syndrome, and other functional somatic conditions.

Over the past decade, the scientific understanding of fibromyalgia has shifted decisively from a peripheral or purely inflammatory problem toward a condition of central sensitization, altered pain modulation, neuroinflammation, and contributions from the neuroendocrine and autonomic nervous systems.

The clinical picture varies so much between patients that fibromyalgia is now best understood as a spectrum of conditions rather than a single uniform disease. That reframing is the backbone of the most recent evidence review and of this article.

Pharmacological therapies: refinement, not revolution

The headline finding from the 2025 literature is sober but useful: no major new drug class arrived. Instead, advances came from refining how existing medicines are formulated, repurposed, and matched to the right patient. Most effective agents act on central mechanisms such as descending pain-inhibition pathways, synaptic excitability, and neuroimmune signalling. Each approach tends to help a specific symptom domain rather than the whole fibromyalgia condition.

SNRIs and gabapentinoids: still the backbone

Serotonin–norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and milnacipran strengthen the body's own descending pain-inhibition system by increasing available serotonin and norepinephrine. Recent data emphasize the noradrenergic system's role in dampening spinal pain transmission, and suggest these drugs may also influence neuroimmune activity, including microglial activation and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).

Gabapentinoids, like pregabalin, reduce neuronal hyperexcitability by acting on the α2δ subunit of voltage-gated calcium channels. They remain among the most evidence-supported options for nociplastic pain, though attention has increasingly turned to safety (weight gain, sedation, and respiratory-depression risk when combined with opioids).

A large observational study of more than 57,000 older adults found no increased fall risk versus duloxetine.

Collectively, these agents offer moderate benefit for roughly 30–50% of patients, with wide individual variability.

Sublingual cyclobenzaprine (TNX-102 SL): the notable new formulation

Approved in the United States in August 2025, sublingual cyclobenzaprine (TNX-102 SL) is the year's most relevant pharmacological innovation. Its under-the-tongue delivery allows rapid absorption and a pharmacokinetic profile suited to bedtime dosing. It directly targets sleep disturbance, a core fibromyalgia domain.

Pooled trial data (four RCTs, 1,684 patients) showed it significantly increased the proportion of patients achieving ≥30% and ≥50% pain reduction versus placebo. Its effect on overall disease burden (measured by the revised Fibromyalgia Impact Questionnaire, FIQR) was inconsistent, suggesting the benefit is domain-specific for mainly pain and sleep, rather than disease-modifying.

Repositioned and emerging agents

Low-dose naltrexone (LDN) is among the most discussed repurposed drugs. Although a recent meta-analysis did not show superiority over controls for chronic pain overall, a signal of benefit emerged specifically in the fibromyalgia subgroup. Its proposed mechanism leads to dampening microglial activation and downstream neuroinflammation. This fits the neuroimmune model of fibromyalgia, but the evidence remains limited by small, heterogeneous studies. Patient reported feedback is very positive.

More experimental directions include psychedelic compounds (psilocybin, LSD, DMT), which may modulate pain via 5-HT2A receptor activation and enhanced neuroplasticity, and intravenous lidocaine for selected refractory patients. Both remain investigational for fibromyalgia. It is mechanistically interesting, but without robust clinical trial evidence yet.

Nutraceuticals such as high-dose omega-3 and combinations of CoQ10, magnesium, and tryptophan have shown domain-specific benefits (pain, sleep) but should not be considered routine care.

Adapted from Bazzichi et al. (2026). Benefits are moderate and domain-specific, with substantial variability between patients.

Non-pharmacological therapies: the real cornerstone

If drug therapy is refinement, non-drug therapy is where FM management genuinely lives. The 2025 evidence reinforces that how an intervention is delivered, supervised, personalized, and sustained often matters more than which specific intervention is chosen.

Exercise and rehabilitation: still first-line

Exercise remains the most consistently supported non-pharmacological intervention. The key insight is that the innovation is not "exercise" itself but its delivery be structured, individualized prescriptions that define modality, intensity, frequency, and progression, starting gently and building only as the patient tolerates it.

Digitally supervised and remote programs when combined with medication in some trials, produced more reliable, lasting improvements in pain, sleep, and quality of life, This underscores the role of adherence and structured follow-up. Low-to-moderate-intensity aquatic exercise suits patients with high fatigue or fear of symptom flares, and mind–body approaches (Qigong, Ba-Duan-Jin) show benefits across pain, fatigue, sleep, and mood.

Neuromodulation and instrumental therapies

Techniques such as transcranial direct current stimulation (tDCS) and transcutaneous vagal nerve stimulation (tVNS) target central sensitisation, autonomic imbalance, and neuroplasticity. Evidence suggests modest but potentially meaningful benefits, especially when combined with rehabilitation, but heterogeneous protocols and small studies mean these are best positioned as adjuncts for selected or refractory patients, not stand-alone cures. Virtual reality, photobiomodulation, and neurofeedback remain promising but experimental.

Psychological, educational, and self-management care

Psychological interventions are not "ancillary". They target core mechanisms of symptom amplification such as fear-avoidance, emotional dysregulation, and alexithymia. Cognitive behavioural therapy (CBT), including accessible online and exposure-based formats, remains well supported. Emerging evidence for psychodynamic, positive-psychology, and emotion-focused approaches points toward matching the therapy to the patient's psychological profile.

Structured education and self-management programs improve coping, symptom interpretation, and adherence. Continued long-term support emerges as a decisive factor in success. Screening for trauma and PTSD is increasingly recommended, given their association with greater FM severity.

Diet, the gut–brain axis, and complementary therapies

Diet is best viewed not as a stand-alone treatment but as a modulator of disease expression acting through the gut microbiota, inflammation, and metabolic balance. Anti-inflammatory and Mediterranean-style patterns show promise, particularly in patients with prominent IBS or metabolic features.

One of the most innovative 2025 findings was a randomized, double-blind trial of an ozonated-water enema that improved pain, anxiety, and sleep while measurably shifting the gut microbiome and reducing duloxetine use which is an intriguing early signal for gut–brain approaches.

Manual and complementary therapies (acupuncture, dry needling, myofascial release, massage) offer modest but clinically relevant relief for pain and muscle tension, especially in myofascial-predominant patients, and work best inside a multimodal program.

The big idea: phenotype-driven, personalized treatment

The single most important conceptual advance is the move away from treating fibromyalgia as one homogeneous condition. Since treatment response is so variable, the evidence now supports identifying clinically meaningful subgroups and matching therapy to each patient's dominant profile. This is why two patients with the same diagnosis may need very different plans.

Adapted from the phenotype-driven model in Bazzichi et al. (2026).

What this means for patients and clinicians. Ask which symptom domain dominates. Is it pain, sleep, fatigue, mood, or gut symptoms? Then build the plan around it. The best outcomes in 2025 came from multimodal programs that combined exercise, psychological support, education, and selected medications, with adherence and continuity of care treated as core ingredients rather than afterthoughts.

Limitations and where the science is heading

Honest caveats remain. Much of the evidence is limited by heterogeneous study designs, small samples, short follow-up, and inconsistent outcome measures. This weakens the strength of firm recommendations.

No single intervention has shown a robust, universal effect. Most treatments produce domain-specific gains (typically pain, sleep, or quality of life), while fatigue, cognitive symptoms, and global disability remain stubborn.

The field's central unmet need is accurate patient stratification, which would include a reliable way to predict which patient will respond to which treatment, and when. Future research is expected to move beyond average treatment effects toward phenotype-based trial designs that integrate clinical, biological, and biomarker data. The reframing is powerful: the challenge is no longer identifying treatments for FM, but understanding which patients benefit from which strategy.

Frequently Asked Questions

What is the most effective treatment for fibromyalgia?

There is no single most effective treatment. The strongest evidence supports a multimodal approach that combines structured exercise, psychological therapy, patient education, lifestyle changes, and selected medications tailored to the patient's dominant symptoms.

Is fibromyalgia a nociplastic pain condition?

Yes. Fibromyalgia is currently classified as a nociplastic pain syndrome, meaning the pain arises mainly from altered central pain processing (central sensitization) rather than ongoing tissue damage or inflammation.

Does low-dose naltrexone (LDN) work for fibromyalgia?

Evidence is promising but preliminary. A recent meta-analysis found a signal of benefit specifically in fibromyalgia, likely through reducing neuroinflammation, but studies remain small and heterogeneous, so LDN is not yet a standard therapy. Patient reported outcomes are highly positive.

What is sublingual cyclobenzaprine (TNX-102 SL)?

It is an under-the-tongue formulation of cyclobenzaprine approved in the U.S. in 2025. FDA approved. It is designed for bedtime dosing to improve sleep and reduce pain. Its benefit appears domain-specific rather than disease-modifying.

Can diet and the gut microbiome affect fibromyalgia?

Emerging evidence links the gut–brain axis, microbiota, and inflammation to fibromyalgia symptoms. Diet is best seen as a modulator of disease expression. Dietary changes are especially helpful for patients with IBS and metabolic features.

References:

1. Bazzichi, L., Di Carlo, M., Salaffi, F., Farah, S., Porta, F., Ablin, J. N., Varrassi, G., Galli, F., Fornasari, D., Carotti, M., Alciati, A., Pellegrino, G., Batticciotto, A., Lucini, D., Casale, R., Di Franco, M., Sarzi-Puttini, P., & Iannuccelli, C. (2026). Therapeutic advances in fibromyalgia: One year in review 2026. Clinical and Experimental Rheumatology, 44(6), 1069–1081. https://doi.org/10.55563/clinexprheumatol/xscnij
2. Iannuccelli, C., Favretti, M., Dolcini, G., et al. (2025). Fibromyalgia: One year in review 2025. Clinical and Experimental Rheumatology, 43(6), 957–969.
3. Blair, H. A. (2026). Sublingual cyclobenzaprine: First approval. Clinical Drug Investigation, 46(1), 107–114.
4. Hegde, N. C., Mishra, A., V, D., et al. (2025). Low-dose naltrexone in the management of chronic pain syndrome: A meta-analysis of randomized controlled clinical trials. Current Pain and Headache Reports, 29(1), 96.
5. Hou, Q., Zhang, J., Su, Z., et al. (2025). Clinical trial of ozonated water enema for the treatment of fibromyalgia: A randomized, double-blind trial. Pain Physician, 28(1), E13–E22.

Medical disclaimer. This article is an educational summary of published research and is not medical advice. Fibromyalgia management should be individualised in consultation with a qualified healthcare professional. Do not start, stop, or change any treatment based on this content alone.